PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma

BACKGROUND: Limited data exist on safe discontinuation of antiprogrammed cell death protein 1 (PD-1) therapy in responding patients with advanced melanoma. The use of 18fluorodeoxyglucose ((18)FDG)-PET/CT scan and tumor biopsy for assessment of active disease may be an effective predictive biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibney, Geoffrey T., Zaemes, Jacob, Shand, Shelly, Shah, Neil J., Swoboda, David, Gardner, Kellie, Radfar, Arash, Petronic-Rosic, Vesna, Reilly, Michael J., Al-Refaie, Waddah B., Rapisuwon, Suthee, Atkins, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488718/
https://www.ncbi.nlm.nih.gov/pubmed/34599027
http://dx.doi.org/10.1136/jitc-2021-002955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488718/
https://www.ncbi.nlm.nih.gov/pubmed/34599027
http://dx.doi.org/10.1136/jitc-2021-002955

Ejemplares similares